Our findings suggest that the therapeutic targeting of TAMs may be important in enabling CD8 + cells to access the tumour, further enhancing and synergising current immune checkpoint-based immunotherapy in ARID1A mutant patients [42,43,44,45,46,47,48,49,50]. The gene discussed is ARID1A; the disease is neoplasm.